Phesi, a clinical development analytics provider, has rolled out a new AI-based platform it claims will save customers an average of $7 million per phase 3 trial.
In an October 18th press release, Phesi announced the platform, named Trial Accelerator, leverages clinical study data to "deliver a comprehensive and consistent view of the patient throughout the process," allowing study teams to construct improved trials with a higher degree of success.
Click here to read the entire article.